Insulet highlights ‘growing power’ of Omnipod

ACTON, Mass. – Insulet Corp. reported revenue of $275.6 million for the third quarter of 2021, up 17.8% over the same period last year. 

It reported revenue was $260.3 million, up 22.7%, for Omnipod. 

"Our third quarter results reflect the growing power of Omnipod,” said Shacey Petrovic, president and CEO. “We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations. We continue to share compelling clinical data that demonstrates the improved outcomes and quality of life Omnipod offers to people of all ages. We remain on track for Omnipod 5 clearance later this year and cannot wait to bring this transformational product to market and further our mission of improving the lives of people with diabetes." 

Insult reported net income was $12.6 million for the third quarter this year vs. $11.6 million for the same period last year. 

Among the recent clinical data the company highlighted: 

• Omnipod 5 Automated Insulin Delivery System pivotal extension results demonstrating statistically significant improved safety and glycemic outcomes observed in the three-month Omnipod 5 pivotal study were maintained over 12 months of home use. 
• Omnipod DASH results from the company’s largest cohort study of people living with Type 1 diabetes demonstrated a significant decrease in A1c after 90 days of use for children, adolescents, and adults. 
• Published results in Diabetes Technology & Therapeutics demonstrated a CGM-informed bolus calculator was safe when used with Omnipod 5 in manual mode, with fewer hypoglycemic readings in the post-bolus period compared to a standard bolus calculator. 

Insulet expects to generate revenue growth of 19% to 25% for the fourth quarter and 18% to 20% for the full year.